I have come to the concIusion that this joint venture is very interesting and that it may have a significant effect on the pps as earIy as this year. I suggest you read the information on the website of Atrin. Here is a IittIe of the information:
"Atrin’s products represent a new approach for treating many solid tumors that currently have limited or ineffective therapies, including breast, pancreatic, lung, ovarian and colon cancers. ?
??
The main limitation of existing cancer treatments, such as chemotherapy, is their unwanted side effects and toxicity. Atrin’s pipeline products all act systemically in the body, reducing ATR activity with remarkably high specificity, stalling the lifespan of cancer cells and causing them to self-destruct, while still projected to leave healthy tissues unaffected. Atrin believes these differential advantages in potency and tolerability will make Atrin's products the best-in-class DDR products in the long run."